$VERAVera Therapeutics, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
  Otsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month…
  biospace · 3d ago
• Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
  The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
  biopharma_dive · 6d ago
• Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
  The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.
  biospace · 7d ago
• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 7d ago
• Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
  Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…
  biopharma_dive · 8d ago
• Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
  Though it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two disease-controlling drugs it already discovered in-h…
  endpoints · 8d ago
• Boulevard starts up with $65M to pursue targeted autoimmune drugs
  Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
  biopharma_dive · 8d ago
• Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
  Boulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.
  fiercebiotech · 9d ago
• Silence causes uproar in rare blood cancer space as data sets high bar for competitors
  The mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…
  biospace · 9d ago
• Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
  Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...
  endpoints · 10d ago